9 results about "Marbofloxacin" patented technology

The application discloses a nickel-based metal organic framework and a preparation method and detection application thereof. The nickel-based metal organic framework is formed by coordination of 2,6-bis(1H-pyrazol-1-yl) isonicotinic acid (H2BPIA) and nickel ions Ni(II). The H2BPIA and NiCl2·6H2O are prepared by a hydrothermal / solvothermal method in a water-acetonitrile mixed solvent, and the obtained nickel-based metal organic framework has high thermal stability and can be used for detection of marbofloxacin and has the advantages of high selectivity, strong anti-environmental interference capability and fast response speed.

The invention discloses a proportional molecularly imprinted electrochemical sensor, a preparation method thereof and application of the proportional molecularly imprinted electrochemical sensor in marbofloxacin detection. The sensor comprises a working electrode, the working electrode sequentially comprises an electrode substrate, a functional material layer and a molecularly imprinted polymer layer, the functional material layer comprises a conductive composite material and Ag nanoparticles deposited on the surface of the conductive composite material, and the conductive composite material comprises a black phosphorus nanosheet modified by a bimetallic MOF material; the molecularly imprinted polymer layer is prepared from a functional monomer and a template molecule, and the template molecule has electrochemical activity. According to the invention, the ratio of the response peak current of MAR and other electrochemical active template molecules to the response peak current of AgNPs is innovatively adopted as a sensing signal, and a signal switch type ratio molecularly imprinted electrochemical sensor is constructed, so that the reliability and sensitivity of detection of MAR and other antibiotic compounds are remarkably improved.

The utility model discloses an energy-saving double-cone dryer for marbofloxacin production, which relates to the technical field of double-cone dryers and comprises a drying tank body, a mounting bracket and a waste water vapor storage tank are sequentially arranged at two ends of the drying tank body, and the drying tank body is sequentially connected with the mounting bracket and the waste water vapor storage tank through a rotating mechanism; a water outlet is formed in one side of the waste water vapor storage tank, and a waste water vapor collecting mechanism matched with the drying tank body is arranged at the top end of the waste water vapor storage tank; a feeding port is formed in the middle of the top of the drying tank body, and temperature equalizing assemblies are arranged on the outer side of the top circumference and the outer side of the bottom circumference of the drying tank body. By arranging the rotating mechanism, fused materials are put into the drying tank body, and the rotating mechanism is used for driving the drying tank body to perform rotary drying, so that the production efficiency and the product quality are improved, sufficient contact between reactants is ensured, the reaction speed is increased, and the production efficiency is improved.

This invention discloses a mabofloxacin intermediate, belonging to the field of drug synthesis technology. First, aminomethylamine and methyl formate are condensed at low temperature to generate MBX-1. Then, a fluoroquinolone core is constructed using a stepwise process of high-temperature acylation condensation, low-temperature nucleophilic substitution, and intermediate-temperature cyclization to obtain MBX-6. Next, in an optimized toluene system, N-methylpiperazine is introduced into the core via high-temperature nucleophilic substitution. After multi-step purification, MBX-7 is obtained. Finally, the quinolone skeleton is reconstructed through an integrated alkaline hydrolysis-acid-catalyzed cyclization process, followed by temperature-controlled recrystallization purification to obtain mabofloxacin intermediate MBX-9. This invention achieves high-purity, low-residue, and high-yield preparation of mabofloxacin intermediates by establishing a DMF-free green solvent system and a precise temperature control strategy. This effectively solves the industrialization problems of excessive residues, increased side reaction impurities, and low overall yield caused by the use of hazardous solvents in existing technologies.

The invention discloses a marbofloxacin pharmaceutical sewage treatment mechanism, and relates to the pharmaceutical sewage treatment technology, the marbofloxacin pharmaceutical sewage treatment mechanism comprises a treatment cylinder body and a medicament channel installed on the left side and the right side of the upper part of the treatment cylinder body in a penetrating manner; a separation mechanism is arranged at the top end of the treatment barrel body, the separation mechanism comprises a separation box body, and a separation cone is arranged at the upper part in the separation box body; buffering transverse grooves are formed in the outer portion of the separation cone at equal intervals, and separation groove holes are formed in the buffering transverse grooves at equal intervals. A treatment mechanism is arranged in the treatment cylinder body, and the treatment mechanism comprises a filter sieve tray. According to the sewage treatment mechanism for marbofloxacin pharmacy, sewage and internal solids are subjected to separation treatment through the separation cone, the solids are intermittently discharged outwards, and the treatment cone in the treatment cylinder body is matched with the mixing rotating shaft to intermittently rotate, so that mixing of the sewage and chemicals is assisted, and the mixing treatment effect is improved.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.

The invention discloses a one-pot method for green and efficient preparation of marbofloxacin, and the method comprises the following steps: carrying out hydrolysis reaction on 6, 8-difluoro-1-(methylamino)-7-(4-methylpiperazine-1-yl)-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (a substrate I) to prepare an intermediate I; the intermediate I is cyclized to obtain marbofloxacin, a main alkali and auxiliary alkali compounded system is adopted in the hydrolysis reaction, the main alkali is sodium hydroxide or potassium hydroxide, and the auxiliary alkali is tetrasodium iminodisuccinate. A KOH / IDS-Na compound system is adopted, the reaction conditions are mild, the reaction time is short, the consumption is small, and the severe conditions that a large amount of tetramethylammonium hydroxide is used and the temperature is high in the literature can be avoided. In the cyclization reaction, an HCl / paraformaldehyde system is adopted, so that the problem of nonuniformity of a formaldehyde aqueous solution in production operation can be avoided; the marbofloxacin is directly and greenly synthesized under mild conditions, the marbofloxacin can be obtained only through simple filtration subsequently, the yield is effectively improved, energy is saved, waste is reduced, the production cost is greatly reduced, and the method is suitable for industrial production.

The invention relates to the technical field of medicine synthesis, and provides a marbofloxacin synthesis method which comprises the following steps: taking 6, 7, 8-trifluoro-1-(formyl methyl amino)-4-oxo-1, 4-dihydroquinoline-3-ethyl formate and N-methyl piperazine as main raw materials to react to obtain an intermediate; and carrying out methyl etherification cyclization reaction on the intermediate in the presence of sulfonated mesoporous silica, cooling, crystallizing, and recrystallizing to obtain marbofloxacin. Wherein the sulfonated mesoporous silica is obtained by impregnating modified mesoporous silica with concentrated sulfuric acid and sulfonating, and the modified mesoporous silica is obtained by modifying mesoporous silica with 1, 2, 8-octantriol. According to the technical scheme, the problem of low marbofloxacin yield in related technologies is solved.

The present invention relates to a formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, antifungal, and an anti-inflammatory in a thick, otic carrier. In one embodiment, the formulation comprises a therapeutically effective amount of active ingredients including a marbofloxacin, terbinafine and / or clotrimazole and dexamethasone.